Brain Health

White adults in their midlife showed slower brain aging than Black and Latinx individuals, but between mid- and late life, they showed increased signs of aging.

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.

Prior research has associated early adolescent use of hormonal contraceptives with the risk of depression in adulthood.

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules.

Five hours or less hours of sleep per night at 50 years of age was associated with a 25% higher risk of mortality over 25 years of follow-up.

Patients with Alzheimer disease administered gantenerumab did experience slower clinical decline, however, it was not deemed statistically significant.

A new study suggests that 30.5% of US adults lose out on 1 hour or more of sleep due to disturbances.

Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Deutetrabenazine is the only VMAT2 inhibitor approved by the FDA for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington disease.

Although the treatment of motor symptoms is the primary focus of care for Parkinson disease, helping these patients with sleep disorders is vital because of the impact on quality of life.

The new data came from Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled (SHARP) study.

New research about the risks of dementia in patients with non-affective psychotic disorders could help shape new life course models for prevention.

The history of targeting neuroinflammation is a good example of the challenges to finding a treatment for Alzheimer disease.

In a study of 2262 individuals, investigators also found that cocoa extract had no effect on cognition.

Changing one’s diet could change brain health and study results suggest the Mediterranean diet could positively support cognitive function.

Research suggests cannabis can improve quality of life for patients who suffer from pain and neurological disorders.

Cognitive harm appears reversible, results of analysis by Nemours Children’s Health Jacksonville and Stanford University shows.

Very short sleep among adolescents linked to a more than 70% increased risk of obesity/overweight in children, compared to those who get optimal 8 hours.

A new study suggests that work and private life mental stressors are disrupting sleep in older employees, potentially wreaking havoc on health.

Investigators used the FDA-approved concussions test i-STAT TBI Plasma and the company’s core laboratory Architect instrument.

The meta-analysis reviews 38 available studies on the effects of cognitive, physical, and social activities on brain function.

Children may have suboptimal long-term brain development if their mother smokes tobacco consistently during pregnancy.

Pharmacists can play an important role in helping ensure compliance with prescribed medications, which can help seniors maintain their health and quality of life while aging at home.

A recent study revealed that social activities like gardening or getting a college degree could improve cognition in older age, which could possibly prevent Alzheimer disease.

Older individuals who were exposed to any amount of light while sleeping were significantly more likely to be obese, have high blood pressure, and have diabetes.

For every 10% increase in daily intake of ultra-processed foods, people had a 25% higher risk of dementia, though the association is not proven to be causal.

The FDA has approved daridorexant (Quviviq; Idorsia Pharmaceuticals, US Inc) to treat adults with insomnia.